Key result
Therapeutic-dose anticoagulation shows no 90-day mortality benefit over prophylactic dosing in critically ill distal PE.
Why the study?
The incidence, management, outcomes, and effects of therapeutic-dose anticoagulation in ICU patients with segmental and subsegmental pulmonary embolism needed to be described and evaluated.
Does therapeutic-dose anticoagulation improve clinical outcomes (mortality, recurrent VTE, bleeding) in critically ill adults with segmental or subsegmental pulmonary embolism?
Cohort (n=104)
No
Does therapeutic-dose anticoagulation improve clinical outcomes (mortality, recurrent VTE, bleeding) in critically ill adults with segmental or subsegmental pulmonary embolism?
This study highlights that while therapeutic anticoagulation is widely used for distal PE in the ICU, it is not associated with improved clinical outcomes and carries a substantial bleeding risk.
Therapeutic anticoagulation should not yet alter practice for distal PE in the ICU; hypothesis-generating and requires prospective trials to clarify net benefit.
Objective To describe the incidence, management, and outcomes of segmental and subsegmental pulmonary embolism (PE) in intensive care unit (ICU) patients and to explore associations between therapeutic-dose anticoagulation and clinical outcomes. Design Single-center retrospective cohort study. Setting Tertiary academic hospital ICU between January 2019 and June 2025. Patients Critically ill adults (≥18 years) who underwent computed tomography pulmonary angiography (CTPA) during ICU admission and had radiologically confirmed segmental or subsegmental PE. Interventions None. Measurements and main results Radiology reports of all CTPA examinations performed in ICU-admitted patients were screened to identify the most proximal level of thrombus. Clinical records were reviewed for demographics, illness severity, radiologic characteristics, anticoagulation practice, bleeding, venous thromboembolism (VTE) recurrence, and mortality. Among 896 CTPA examinations performed in 804 patients, 164 examinations (18.3%) identified PE. Of these, 115 scans (12.8% of all CTPAs) demonstrated distal PE only, corresponding to 104 patients (12.9%) (61 segmental, 43 subsegmental). Overall, 96% of patients with distal PE received anticoagulation and 86% of anticoagulated patients received therapeutic-dose regimens. Bleeding occurred in 15% (major bleeding 12%), 90-day VTE recurrence in 7.8%, and 90-day mortality in 24%. No statistically significant association was found between the use of therapeutic-dose anticoagulation and 90-day mortality (adjusted odds ratio [OR], 0.70; 95% CI, 0.21–2.45), bleeding episodes (adjusted OR, 2.34; 95% CI, 0.47–19.2), or VTE recurrence (adjusted OR, 0.69; 95% CI, 0.11–6.22). Conclusions In critically ill adults, segmental and subsegmental PE are commonly detected on CTPA and are usually treated with therapeutic-dose anticoagulation. Although VTE recurrence was less frequent than bleeding episodes and mortality, our study did not find a significant association between therapeutic-dose anticoagulation and bleeding episodes, recurrent VTE, or mortality. Larger prospective studies are needed to define optimal anticoagulation strategies for ICU patients with distal PE.
No takes yet. Share an insight, caveat, or question.
Kitisin et al. (2026) conducted a cohort in Segmental and subsegmental pulmonary embolism in ICU patients (n=104). Therapeutic-dose anticoagulation vs. Non-therapeutic dose anticoagulation was evaluated on 90-day mortality (adjusted OR 0.70, 95% CI 0.21-2.45). In critically ill adults with distal pulmonary embolism, therapeutic-dose anticoagulation was not significantly associated with 90-day mortality (adjusted OR 0.70, 95% CI 0.21-2.45), bleeding, or recurrent VTE.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: